Ritter Pharmaceuticals Selects Medpace as its Clinical Research Organization for Pivotal Phase 3 Clinical Trial of RP-G28 in Lactose Intolerance
03 mai 2018 06h00 HE
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 03, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut...